Fortrea Holdings Inc. (FTRE) Stock Price & Analysis
Fortrea Holdings Inc. (FTRE) rose 1.87% to USD 16.88 as of June 10, 2026 at 10:44 UTC, according to Nexqual real-time market data.
FTRE last closed at USD 16.57; the session ranged USD 16.09–17.34 on volume of 865,995 shares. Market capitalization is $1.60B, with a 52-week range of USD 4.36–18.67 (NMS). Source: Nexqual, June 10, 2026 at 10:44 UTC.
Key Statistics (as of June 10, 2026 at 10:44 UTC)
| Price | USD 16.88 |
|---|---|
| Change | ▲ 1.87% (up) |
| Previous Close | USD 16.57 |
| Open | USD 17 |
| Day Range | USD 16.09 – 17.34 |
| 52-Week Range | USD 4.36 – 18.67 |
| Volume | 865,995 shares |
| Market Cap | $1.60B |
| Exchange | NMS |
Technical Analysis (FTRE)
Nexqual's technical model rates FTRE "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 10:44 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 68.13 (neutral) |
| vs SMA50 | Above (USD 12.3) |
| MACD | 1.07 (positive) |
Analyst Ratings (FTRE)
Wall Street analysts rate FTRE "Buy" based on 11 analysts, with a mean price target of USD 16.21 (range USD 9.5–20), per Nexqual as of June 10, 2026 at 10:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 16.21 |
| High Target | USD 20 |
| Low Target | USD 9.5 |
| Buy / Hold / Sell | 5 / 5 / 2 |
Earnings (FTRE)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.18 |
| Revenue Estimate | $647.61M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.16 vs est 0.05 ▲ beat |
| 2025-12-31 | USD 0.09 vs est 0.16 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.16 ▼ miss |
| 2025-06-30 | USD 0.19 vs est 0.08 ▲ beat |
Source: Nexqual, June 10, 2026 at 10:44 UTC.
Financials & Fundamentals (FTRE)
| Total Revenue | $2.71B |
|---|---|
| Revenue Growth (YoY) | -2.30% |
| Gross Margin | +18.86% |
| Operating Margin | +0.52% |
| Profit Margin | -16.50% |
| ROE | -64.55% |
| Debt / Equity | 212.7 |
| Current Ratio | 0.95 |
| Total Cash | $147.50M |
| Total Debt | $1.12B |
| Free Cash Flow | $285.61M |
Source: Nexqual, June 10, 2026 at 10:44 UTC.
Financial Health Score (FTRE)
Nexqual rates Fortrea Holdings Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 10:44 UTC.
| Growth | Mixed — Revenue +1.0% YoY (annual), slow |
|---|---|
| Profitability | Weak — Gross margin 19%, operating 1% |
| Balance Sheet | Critical — $148M cash vs $1.12B debt |
| Cash Flow | Solid — FCF $286M, 10% margin |
| Efficiency | Critical — ROE -65%, ROA -0.1% |
Ownership (FTRE)
| Insider Ownership | +0.83% |
|---|---|
| Institutional Ownership | +109.95% |
| Shares Outstanding | 94.58M |
| Float | 93.88M |
| Short % of Float | +11.79% |
Source: Nexqual, June 10, 2026 at 10:44 UTC.
Leadership (FTRE)
Fortrea Holdings Inc. is led by Anshul Thakral (age 47), CEO & Director, per Nexqual as of June 10, 2026 at 10:44 UTC.
| CEO & Director | Anshul Thakral (age 47) |
|---|---|
| Chief Financial Officer | Jill McConnell (age 50) |
| COO & President of Clinical Services | Mark A. Morais (age 48) |
| President & Chief Commercial Officer | Drayton Virkler |
Major Backers & Investors (FTRE)
Notable institutional backers of Fortrea Holdings Inc. include Goldman Sachs, Corvex Management LP, Sessa Capital IM, L.P., according to Nexqual as of June 10, 2026 at 10:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Goldman Sachs | 8.56% |
| Corvex Management LP | 4.91% |
| Sessa Capital IM, L.P. | 4.86% |
| AQR Capital Management, LLC | 3.49% |
| Charles Schwab Investment Management, Inc. | 3.39% |
| Fidelity | 2.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 24.3% |
| Vanguard Group | 13.47% |
| State Street | 4.34% |
| Deutsche Bank AG | 2.72% |
Source: Nexqual, June 10, 2026 at 10:44 UTC.
From Fortrea Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property In the course of conducting our business, we have developed, and continue to develop and use, proprietary software, systems, processes, databases and other intellectual property.
- We seek to protect our proprietary and confidential information and trade secrets through confidentiality agreements with employees, customers, and other third parties, as well as through administrative and technical safeguards.
- We believe our broad customer base positions us at the forefront of innovation in healthcare and allows us to help our customers efficiently bring the best therapeutic solutions to patients.
- Our integrated clinical pharmacology solution supports the increasing complexity in early phase trials with precision, quality and safety.
Partnerships
- On March 9, 2024, the Company, together with its wholly-owned subsidiary, Fortrea Inc., entered into an Asset Purchase Agreement (the "Purchase Agreement") with Endeavor Buyer LLC, an affiliate of Arsenal Capital Partners, to sell the operations of Fortrea Patient Access Inc. and its subsidiaries and Endpoint Clinical, Inc. and its subsidiaries; which are all collectively referred to as the Enabling Services Segment.
- The insights gathered show consistent alignment with industry benchmarks and demonstrate meaningful progress across key engagement drivers, including collaboration, inclusion, and confidence in leadership.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| ELVN | Enliven Therapeutics, Inc. | USD 36.11 | ▲ 4.03% |
| APGE | Apogee Therapeutics, Inc. | USD 85 | ▼ 2.21% |
| NMRA | Neumora Therapeutics, Inc. | USD 1.65 | ▲ 1.23% |
| VSTS | Vestis Corporation | USD 12.87 | ▲ 0.16% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 10:44 UTC. This page is informational and not investment advice.